- Market Capitalization, $K 3,752,516
- Shares Outstanding, K 30,890
- Annual Sales, $ 12,730 K
- Annual Income, $ -295,160 K
- 60-Month Beta 2.23
- Price/Sales 286.44
- Price/Cash Flow N/A
- Price/Book 5.01
|Period||Period Low||Period High||Performance|
| || |
-7.44 (-5.77%)since 09/20/19
| || |
-43.98 (-26.58%)since 07/19/19
| || |
-21.11 (-14.80%)since 10/19/18
GW Pharmaceuticals PLC (GWPH) closed the most recent trading day at $118.11, moving -0.85% from the previous trading session.
Abbott (ABT) collaborates with Omada Health to revolutionize diabetes care by expanding technological access.
Over the next three days, Canada will legalize CBD all over again. Just a year after legalizing dried cannabis flower, oils, and sprays, Canada will now legalize edibles, beverages, and topicals this Thursday,...
CHF Solutions' (CHFS) Aquadex system to be used for the outpatient study on heart failure, conducted by James A. Haley Veterans' Hospital and Clinics. The study receives final approval.
Per Phibro Animal (PAHC), weak demand in Animal Health business due to swine flu outbreak in China along with an unfavorable product mix in Mineral Nutrition is dampening.
Penumbra (PEN) gears up for the study of mechanical power aspiration as part of advancements in coronary treatment.
As the cannabis market booms, another drug may soon follow in its footsteps -- psilocybin mushrooms. Already, we're seeing a groundswell of interest. In fact, activists in California are working on getting...
QIAGEN (QGEN) aims to fast-track the adoption of NGS-based IVD test and improve patient outcomes through the new partnership deal.
Investors are still crazy about the pot stocks despite this year's roller coaster ride.
Is (GWPH) Outperforming Other Medical Stocks This Year?